Document Detail

Monitoring cell therapy using iron oxide MR contrast agents.
MedLine Citation:
PMID:  15579045     Owner:  NLM     Status:  MEDLINE    
Given the remarkable progress that has recently been obtained in animal studies, the clinical use of stem and progenitor cells to correct or replace defective cell populations may soon become a reality. In order to develop effective cell therapies, the location and distribution of these cells must be determined in a non-invasive manner. Magnetic resonance (MR) tracking of magnetically labeled cells following transplantation or transfusion may fulfill this requirement. Indeed, a series of recent studies indicate that MRI cell tracking has great potential for further evaluation and optimization of cell therapy. Due to its biocompatibility and strong effects on T2(*) relaxation, iron oxide nanoparticles appear to be the contrast agent of choice, and several methods now exist to shuttle sufficient amount of these compounds into cells. Most of the tracking work has been carried out in disease models of the central nervous system, but, recently, the infarcted heart has also received attention. With its excellent spatial resolution and the ability to track labeled cells over prolonged periods of time, MR monitoring of cell therapy is likely to become an important technique in the foreseeable future.
Jeff W M Bulte; Dara L Kraitchman
Related Documents :
16657225 - Factors related to iron absorption by enzymically isolated leaf cells.
6604935 - Leucocyte-associated plasma proteins. association of prealbumin, albumin, orosomucoid, ...
11358855 - Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy.
6252945 - Membrane characteristics and metabolic properties of glucose-6-phosphate dehydrogenase ...
3905435 - Resistance to alloxan of tumoral insulin-producing cells.
24078215 - Temozolomide and irradiation combined treatment-induced nrf2 activation increases chemo...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Current pharmaceutical biotechnology     Volume:  5     ISSN:  1389-2010     ISO Abbreviation:  Curr Pharm Biotechnol     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2004-12-06     Completed Date:  2005-03-08     Revised Date:  2008-05-12    
Medline Journal Info:
Nlm Unique ID:  100960530     Medline TA:  Curr Pharm Biotechnol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  567-84     Citation Subset:  IM    
Department of Radiology and Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Count / methods*
Contrast Media*
Drug Delivery Systems / methods*
Ferric Compounds / diagnostic use*
Image Interpretation, Computer-Assisted / methods
Magnetic Resonance Imaging / methods*
Molecular Biology / methods
Molecular Probe Techniques*
Molecular Probes
Tissue Therapy / methods*
Grant Support
Reg. No./Substance:
0/Contrast Media; 0/Ferric Compounds; 0/Molecular Probes; 1309-37-1/ferric oxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A non-invasive approach to detecting organ rejection by MRI: monitoring the accumulation of immune c...
Next Document:  Progress in the development of melanocortin receptor selective ligands.